ponatinib
otsuka,takeda,incyte
['ponatinib']
if the 6yr follow up also presented at #ash2022 of hypercvad + ponatinib is any indication, i wouldn t expect longer follow up to diminish the amazing success seen here 
Assistant Professor Leukemia Program @weillcornell @nyphospital @wcmleukemia | Novel therapeutics and improving outcomes in AML and ALL